stooocks.com

Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.

Jubilant Pharmova Limited

India · NSE: JUBLPHARMA.NS · Market cap: · P/E: · P/S:

Jubilant Pharmova makes and sells medicines and drug-making services, from radioactive cancer diagnostics to allergy shots to contract manufacturing for other drug companies.

Jubilant Pharmova is a grab-bag of pharmaceutical businesses under one roof. It makes radioactive drugs used in cancer scans, sells allergy shots, fills sterile injectables for other drugmakers, and runs a contract research and manufacturing arm that helps other companies develop and produce medicines. It also sells generic drugs and is developing a few novel drugs of its own. If you picture a drug industry supply chain, Jubilant sits at several points along it at once.

The most distinctive piece is radiopharma. Jubilant makes radioactive diagnostic products — tiny amounts of radioactive material that get injected into a patient so a scanner can light up cancer or other problems inside the body. This is tricky work: the radioactive ingredients decay quickly, so production, shipping, and timing all have to be tight. That difficulty is also the moat. Few companies can do it well, and hospitals pay for reliability. The allergy immunotherapy business works on a similar logic — it makes the customized allergy extracts that clinics use to desensitize patients over time. Then there's the contract side, which is the quiet engine. Jubilant makes sterile injectables for other companies and runs a CRDMO business — contract research, development, and manufacturing — that takes a molecule from early lab work through to commercial production. Drugmakers outsource this because building and running a compliant factory is expensive and slow. Jubilant gets paid for the work whether or not the customer's drug ultimately becomes a blockbuster, which makes the revenue steadier than selling its own branded medicines. Its generics business rounds things out, selling off-patent drugs in plain, everyday competition where price is what matters. The company is headquartered in India and sells into global markets, especially the United States and Europe, where regulated drug markets demand high manufacturing standards. That's both the opportunity and the risk: a single failed factory inspection can freeze shipments and hit revenue, and regulators in these markets are strict. Jubilant has had to invest heavily in fixing and upgrading plants over the years, and those costs eat into profit. It's a business that rewards patience and capital spending rather than rapid growth.


So how should you think about Jubilant Pharmova? It's less a single story and more a portfolio of specialized pharmaceutical operations, some high-margin and hard to copy, others plain and price-driven. Its strength is being deeply embedded in businesses other companies need but don't want to run themselves. Its vulnerability is that complex manufacturing plus strict regulators equals occasional expensive surprises.

Saved answer · last researched 16 Nov 2026